Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755307 | 0.87 | CASP3 (0.70) | KMT2AALDH1A1MEN1CASP3CHRM5 | |
| SCHEMBL23918746 | 0.86 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1CASP3KDM4E | |
| SCHEMBL23910448 | 0.85 | MEN1 (0.58) | KMT2AALDH1A1MEN1CASP3KDM4E | |
| SCHEMBL24379688 | 0.82 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1CASP3CHRM1 | |
| SCHEMBL6078714 | 0.81 | LIPG (0.43) | KMT2AALDH1A1MEN1CASP3KDM4E | |
| SCHEMBL23918756 | 0.80 | ALDH1A1 (0.51) | KMT2AALDH1A1MEN1CASP3KDM4E | |
| SCHEMBL29428200 | 0.78 | ALDH1A1 (0.48) | KMT2AALDH1A1MEN1CASP3KDM4E | |
| SCHEMBL1839329 | 0.73 | CASP3 (0.69) | KMT2AALDH1A1MEN1CASP3GAA | |
| SCHEMBL28925117 | 0.72 | MEN1 (0.50) | KMT2AALDH1A1MEN1CASP3CDC7 | |
| SCHEMBL23918537 | 0.72 | ALDH1A1 (0.45) | KMT2AALDH1A1MEN1CASP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | KMT2A 4618/4885ALDH1A1 1120/4885MEN1 2887/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | KMT2A 4670/4885ALDH1A1 1149/4885MEN1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.